Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31077517 | 1.00 | MEN1 (0.50) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL31077652 | 1.00 | MEN1 (0.50) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL31077655 | 1.00 | MEN1 (0.50) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL19172278 | 1.00 | MEN1 (0.50) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL9204036 | 1.00 | MEN1 (0.50) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL5849818 | 1.00 | MEN1 (0.50) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL4732986 | 1.00 | MEN1 (0.50) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL5849811 | 1.00 | MEN1 (0.50) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL5849425 | 1.00 | MEN1 (0.50) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL2744123 | 1.00 | MEN1 (0.50) | MEN1KMT2AKDM4CL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022235-B2 | Compositions of phospholipid ether boronic acids and esters and methods for their synthesis and use | CELLECTAR, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-7893286-B2 | Method for the synthesis of phospholipid ethers | CELLECTAR, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20090018357-A1 | Compositions of phospholipid ether boronic acids and esters and methods for their synthesis and use | CELL ACQUISITION CORP. | 2009-01-15 | — | — | US | disclosed |
| US-20080312459-A1 | Method for the synthesis of phospholipid ethers | CELL ACQUISITION CORP. | 2008-12-18 | — | — | US | disclosed |
| US-20070167524-A1 | Capsaicin derivates and the production and use thereof | AXICHEM AB (SE) | 2007-07-19 | — | — | US | disclosed |
| US-20070014756-A1 | Composition and method for treating the gastro-intestinal tract | TOUCHOT NICHOLAS | 2007-01-18 | — | — | US | disclosed |
| US-7153844-B2 | Estrogen-linked platinum (II) complexes as anticancer agents | Berube, Gervais (CA) | 2006-12-26 | — | — | US | disclosed |
| US-20040006051-A1 | Estrogen-linked platinum (II) complexes as anticancer agents | GERVAIS BERUBE (CA) | 2004-01-08 | — | — | US | disclosed |
| EP-0169033-B1 | INHIBITORS OF SLOW REACTING SUBSTANCE OF ANAPHYLAXIS | SCHERING CORPORATION (US) | 1992-02-12 | — | — | EP | disclosed |
| EP-0169033-A2 | Inhibitors of slow reacting substance of anaphylaxis | SCHERING CORPORATION (US) | 1986-01-22 | — | — | EP | disclosed |
| US-4089897-A | Geminal prostaglandin analogs | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1978-05-16 | — | — | US | disclosed |
| US-4090019-A | Geminal prostaglandin analogs | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1978-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167524-A1 | Capsaicin derivates and the production and use thereof | TRPV1, TRPA1, TRPV2 | MEN1 2441/4885KMT2A 1567/4885KDM4C 2432/4885 |
| US-20040006051-A1 | Estrogen-linked platinum (II) complexes as anticancer agents | ESR2, PGR, ESR1 | MEN1 814/4885KMT2A 2911/4885KDM4C 2149/4885 |
| US-20070014756-A1 | Composition and method for treating the gastro-intestinal tract | GIPR, FABP2, FABP6 | MEN1 4171/4885KMT2A 3349/4885KDM4C 4398/4885 |
| US-20090018357-A1 | Compositions of phospholipid ether boronic acids and esters and methods for their synthesis and use | PHOSPHO1, PEBP1, SGMS1 | MEN1 449/4885KMT2A 2096/4885KDM4C 1647/4885 |
| US-20080312459-A1 | Method for the synthesis of phospholipid ethers | PHOSPHO1, PLEC, PLA2G2C | MEN1 365/4885KMT2A 1176/4885KDM4C 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.